Kopran Limited

KOPRAN

INE082A01010

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 08:56:16 16/05/2024 BST			5-day change	1st Jan Change
257.6 ^INR	+3.37%		+7.14%	+7.25%

02-07	Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Kopran Limited Declares Interim Dividend

October 28, 2020 at 08:00 am

Kopran Limited board has declared interim dividend of INR 1.50 per equity share of face value of INR 10 each for the financial year 2020-21.

Latest news about Kopran Limited

Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-07	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-07	CI
Kopran Limited Announces Renewal of Gmp Compliance Certificate by Medicines & Healthcare Products Regulatory Agency of United Kingdom (Mhra - Uk)	01/09/23	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Revises Outlook to Negative	18/08/23	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/08/23	CI
Kopran Limited Recommends Dividend for the Year Ended March 31, 2023	25/05/23	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	25/05/23	CI
Crisil Keeps BBB+ Rating on Kopran's Bank Loans; Outlook Stable	26/04/23	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/02/23	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/11/22	CI
Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India	31/10/22	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/08/22	CI
Kopran Limited Recommends Dividend for the Financial Year 2021-2022	27/05/22	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	27/05/22	CI
Kopran Limited Reports Earnings Results for the Full Year Ended March 31, 2022	27/05/22	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Outlook Stable	20/05/22	MT
Kopran Invests Over $13 Million in Subsidiary	21/03/22	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	03/02/22	CI
Kopran Limited announced that it has received INR 1.264799745 billion in funding from Mahima STOCKS Private Limited, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited	11/01/22	CI
Pharmaceuticals Manufacturer Kopran's Arm Gets New Patent in India	12/12/21	MT
Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investors	07/12/21	CI
Kopran's Board to Consider Issuance of Equity Shares	03/12/21	MT
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	27/10/21	CI
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	06/08/21	CI
Kopran : Arm Resumes Production at Flood-Hit Unit	29/07/21	MT

Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.

Sector

Pharmaceuticals

Calendar

15/05/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOPRAN LIMITED	+7.25%	144M
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+31.00%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.48%	239B
NOVARTIS AG	+9.24%	211B
ROCHE HOLDING AG	-3.56%	203B
AMGEN INC.	+10.77%	171B